The novel oxo-palmatine derivative 2q targets hyperpolarization-activated cyclic nucleotide-gated channel 2 (HCN2) to reduce Aβ deposition and Tau protein phosphorylation, thereby improving Alzheimer’s disease pathological features (Pang et al., 2025). The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.